Gynecology/Obstetrics CME

Credits: 1.50 CME / MOC
Medical Learning Institute, Inc.
Evaluating the Evidence and Parsing the Practicalities of Therapeutic Choices in Advanced and Early HR+ Breast Cancer: Expert Perspectives on CDK4 and 6 Inhibitors and Other Novel Agents
Sara M. Tolaney, MD, MPH
July 7, 2021
Credits: 1.50 CME / MOC / NCPD
Medical Learning Institute, Inc.
The Expanding Advanced Ovarian Cancer Treatment Palette: Candid Conversations on Bringing PARP Inhibitors Into Clinical Practice
Deborah K. Armstrong, MD
July 6, 2021
Credits: 1.50 CME / MOC / NCPD
Medical Learning Institute, Inc.
Making Progress in Early and Advanced HER2-Positive Breast Cancer: Leveraging HER2-Targeted Therapies and Modern Care Principles to Improve Clinical Outcomes and Health Equity
Sara Hurvitz, MD
July 2, 2021
Credits: 1.50 CME / MOC / CC
Medical Learning Institute, Inc.
Expanding the Benefits of Checkpoint Inhibitors and Targeted Agents in the Treatment Arsenal for Triple-Negative Breast Cancer
Joyce O’Shaughnessy, MD
July 2, 2021
Credits: 0.75 CME / MOC / NCPD
Medical Learning Institute, Inc.
Navigating Shifts in the Treatment Landscape for Metastatic HER2-Positive Breast Cancer: Can New HER2-Targeted Therapies Address Unmet Needs and Offer Better Options for Challenging Patient Populations?
Shanu Modi, MD
June 1, 2021
Credits: 0.50 CME / NCPD / CPE
Purdue University College of Pharmacy
Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice
Evan J. Lipson, MD
May 11, 2021
Credits: 1.00 CME / MOC / CC / NCPD
Medical Learning Institute, Inc.
Enhancing Personalized Medicine in Advanced Ovarian Cancer: Expert Guidance on Integrating the Latest Updates on PARP Inhibitors and Novel Therapeutic Innovations Into Your Clinical Practice
May 11, 2021
Credits: 1.50 CME / MOC / CC
Medical Learning Institute, Inc.
Target Practice: Understanding How PARP Inhibitors Take Aim at DNA Damage Response Mutations Across Solid Tumors
Susana Banerjee, MBBS, MA, FRCP, PhD
May 7, 2021
Credits: 0.50 CME
Medical Learning Institute, Inc.
Acute Hepatic Porphyria: Disease Diagnosis and Revelations Regarding the Role of siRNA Therapy
Karl E. Anderson, MD
April 15, 2021
Credits: 1.00 CME / MOC / CC
Medical Learning Institute, Inc.
HER2 and HER3 Alterations as Therapeutic Targets of Increasing Significance in Solid Tumors: Implications for Pathology and Oncology Practice
Kurt A. Schalper, MD, PhD
April 6, 2021
Credits: 1.00 CME / MOC / CC
Medical Learning Institute, Inc.
The Nuances of Immunotherapy Biomarker Testing in Solid Tumors: Unraveling Complexities and Overcoming Challenges to Improve Outcomes
Hossein Borghaei, DO, MS / Sanjay Mukhopadhyay, MD
April 5, 2021
Credits: 0.50 CME
Medical Learning Institute, Inc.
Rewriting the Rules for Early Cancer Screening: Case-Based Insight on Primary Care Principles for Using Blood-Based Screening Techniques
John J. Russell, MD
March 25, 2021
Credits: 0.50 CME / MOC / CE
Medical Learning Institute, Inc.
Innovative Blood-Based Screening in Cancer Care: State of the Science and Future Opportunities for Accelerating Cancer Diagnoses
Minetta C. Liu, MD
March 18, 2021
Credits: 0.50 CME
Medical Learning Institute, Inc.
MS Treatment Decisions Before, During, and After Pregnancy: Focus on the Use of Disease-Modifying Therapies
Maria K. Houtchens, MD, MMs
January 22, 2021
Credits: 1.00 CME
Medical Learning Institute, Inc.
Realizing the Potential of CDK 4/6 Inhibitor Therapy in Breast Cancer: An Examination of the Evidence That Is Informing Real-World Practice
Adam Brufsky, MD, PhD
September 30, 2020
Credits: 1.00 CME / MOC
Medical Learning Institute, Inc.
Making the Most of the New Era of Immuno-Oncology in TNBC: Essential Guidance for Surgeons on How to Maximize the Potential of Immunotherapies and Combinations in Advanced and Early-Stage Breast Cancer
George Plitas, MD
September 21, 2020
Credits: 1.25 CME / MOC / CNE
Medical Learning Institute, Inc.
The Era of Immuno-Oncology in TNBC: Navigating Evidence in Early-Stage and Advanced Disease, Practicalities of Integration, and Implications for Breast Surgeons
George Plitas, MD
August 28, 2020
Credits: 1.50 CME / MOC
Medical Learning Institute, Inc.
Moving in Leaps and Bounds Toward Expanded Precision Treatment of HER2- or HER3-Driven Breast, Gastrointestinal, Lung, and Other Cancers: Current Challenges, Opportunities for Improvement, and Practical Considerations
Erika Hamilton, MD
August 6, 2020
Credits: 1.00 CNE
Medical Learning Institute, Inc.
Rethinking Patient Care in Endometrial and Cervical Cancer: How Nurses Can Lead the Targeted and Immunotherapeutic Revolution
Kimberly Halla, MSN, FNP-C
August 5, 2020
Credits: 1.00 CME
Medical Learning Institute, Inc.
Current and Emerging Therapies for Endometriosis and Uterine Fibroids: What Do You Need to Know?
Georgine Lamvu, MD, MPH
August 3, 2020
Medical Learning Institute, Inc.
Evidence Informing Practice: Changing Standards of Care for Use of CDK4 and 6 Inhibitors in the Treatment of Breast Cancer
Joyce O’Shaughnessy, MD
July 23, 2020
Medical Learning Institute, Inc.
Optimizing Precision Medicine in Ovarian Cancer: Expert Insights on Clinical Implications of PARP Inhibitor Therapy and Companion Diagnostics
Bradley J. Monk, MD, FACS, FACOG
July 21, 2020
Medical Learning Institute, Inc.
Practical Perspectives on Rapid Change in Endometrial and Cervical Cancer Management: Exploring Innovative Therapy in Gynecologic Malignancies
Linda R. Duska, MD, MPH
July 17, 2020
Medical Learning Institute, Inc.
Chair's Take on Harnessing the Immune System in the Treatment of TNBC and Beyond: Where Are We Now and Where Are We Going Next?
Heather L. McArthur, MD, MPH
July 9, 2020
Medical Learning Institute, Inc.
Chair's Take: Latest and Emerging Evidence of PARP Inhibitors in Ovarian Cancer Management
Bradley J. Monk, MD, FACS, FACOG
June 18, 2020
Medical Learning Institute, Inc.
Expert Views on the Evolving Role of PARP Inhibitors in the Treatment of Ovarian Cancer
Bradley J. Monk, MD, FACS, FACOG
April 30, 2020
Medical Learning Institute, Inc.
On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum
Peter Schmid, FRCP, MD, PhD
December 30, 2019
Penn State College of Medicine
Advances in Precision Care in Solid Tumor Oncology: Defining the Role of PARP Inhibitors
Robert Coleman, MD
November 8, 2019

Education Collections